337 related articles for article (PubMed ID: 32010591)
1. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.
Spagnuolo A; Muto M; Monaco F; Colantuoni G; Gridelli C
Transl Lung Cancer Res; 2019 Dec; 8(6):1134-1151. PubMed ID: 32010591
[TBL] [Abstract][Full Text] [Related]
2. Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.
Turkaj A; Morelli AM; Vavalà T; Novello S
Front Oncol; 2018; 8():278. PubMed ID: 30140655
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Berghoff AS; Bellosillo B; Caux C; de Langen A; Mazieres J; Normanno N; Preusser M; Provencio M; Rojo F; Wolf J; Zielinski CC
ESMO Open; 2019; 4(3):e000498. PubMed ID: 31297240
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
5. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
6. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
Tatineni V; O'Shea PJ; Ozair A; Khosla AA; Saxena S; Rauf Y; Jia X; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190312
[No Abstract] [Full Text] [Related]
7. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG; Di Noia V; D'Argento E; Vita E; Damiano P; Cannella A; Ribelli M; Pilotto S; Milella M; Tortora G; Bria E
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397295
[TBL] [Abstract][Full Text] [Related]
8. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
Wrona A; Dziadziuszko R; Jassem J
Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
[TBL] [Abstract][Full Text] [Related]
9. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
11. Brain metastases in oncogene-driven non-small cell lung cancer.
Nishino M; Soejima K; Mitsudomi T
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S298-S307. PubMed ID: 31857953
[TBL] [Abstract][Full Text] [Related]
12. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
13. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
[TBL] [Abstract][Full Text] [Related]
14. Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.
Remon J; Besse B
Front Oncol; 2018; 8():88. PubMed ID: 29696132
[TBL] [Abstract][Full Text] [Related]
15. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
Langston J; Patil T; Ross Camidge D; Bunn PA; Schenk EL; Pacheco JM; Jurica J; Waxweiler TV; Kavanagh BD; Rusthoven CG
Lung Cancer; 2023 Apr; 178():103-107. PubMed ID: 36809719
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
Ahluwalia MS; Becker K; Levy BP
Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
[TBL] [Abstract][Full Text] [Related]
18. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.
El Shafie RA; Seidensaal K; Bozorgmehr F; Kazdal D; Eichkorn T; Elshiaty M; Weber D; Allgäuer M; König L; Lang K; Forster T; Arians N; Rieken S; Heussel CP; Herth FJ; Thomas M; Stenzinger A; Debus J; Christopoulos P
ESMO Open; 2021 Jun; 6(3):100161. PubMed ID: 34090172
[TBL] [Abstract][Full Text] [Related]
19. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
20. The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation.
Cui J; Li L; Yuan S
Front Oncol; 2022; 12():863715. PubMed ID: 35646640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
